Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
| Descriptor ID |
D016159
|
| MeSH Number(s) |
D12.776.157.687.650 D12.776.260.820 D12.776.624.776.775 D12.776.660.720.650 D12.776.744.845
|
| Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- p53 Antigen
- TP53 Protein
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- Cellular Tumor Antigen p53
- Oncoprotein p53
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 4 | 7 |
| 1997 | 2 | 3 | 5 |
| 1998 | 3 | 4 | 7 |
| 1999 | 1 | 1 | 2 |
| 2000 | 3 | 4 | 7 |
| 2001 | 4 | 2 | 6 |
| 2002 | 9 | 9 | 18 |
| 2003 | 7 | 3 | 10 |
| 2004 | 9 | 2 | 11 |
| 2005 | 6 | 4 | 10 |
| 2006 | 8 | 5 | 13 |
| 2007 | 3 | 7 | 10 |
| 2008 | 5 | 11 | 16 |
| 2009 | 3 | 2 | 5 |
| 2010 | 12 | 6 | 18 |
| 2011 | 8 | 9 | 17 |
| 2012 | 5 | 9 | 14 |
| 2013 | 5 | 1 | 6 |
| 2014 | 8 | 5 | 13 |
| 2015 | 7 | 7 | 14 |
| 2016 | 6 | 6 | 12 |
| 2017 | 8 | 4 | 12 |
| 2018 | 5 | 9 | 14 |
| 2019 | 7 | 7 | 14 |
| 2020 | 5 | 4 | 9 |
| 2021 | 5 | 3 | 8 |
| 2022 | 5 | 7 | 12 |
| 2023 | 2 | 10 | 12 |
| 2024 | 8 | 5 | 13 |
| 2025 | 11 | 5 | 16 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias. Blood Adv. 2026 Mar 10; 10(5):1746-1755.
-
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
-
Thymic epithelial cells amplify epigenetic noise to promote immune tolerance. Nature. 2025 Oct; 646(8085):724-733.
-
Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
-
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
-
DDX41 resolves G-quadruplexes to maintain erythroid genome integrity and prevent cGAS-mediated cell death. Nat Commun. 2025 Aug 05; 16(1):7195.
-
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025 Jul 31; 146(5):590-600.
-
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 22; 9(14):3395-3407.
-
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 08; 9(13):3370-3380.
-
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases. Oncoimmunology. 2025 Dec; 14(1):2514041.